Explore

Trendline Trendline
Imperagen Secures $6.7 Million to Revolutionize Enzyme Engineering with AI and Quantum Physics

Imperagen Secures $6.7 Million to Revolutionize Enzyme Engineering with AI and Quantum Physics

Imperagen Secures $6.7 Million to Revolutionize Enzyme Engineering with AI and Quantum Physics
Trendline Trendline
Imperagen Secures $6.7 Million to Innovate Enzyme Engineering with AI and Quantum Physics

Imperagen Secures $6.7 Million to Innovate Enzyme Engineering with AI and Quantum Physics

Imperagen Secures $6.7 Million to Innovate Enzyme Engineering with AI and Quantum Physics
Trendline Trendline
Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform
Trendline Trendline
OpenBind Launches AI Model for Drug Discovery with Extensive Dataset

OpenBind Launches AI Model for Drug Discovery with Extensive Dataset

OpenBind Launches AI Model for Drug Discovery with Extensive Dataset
Trendline Trendline
Incyte and Edison Scientific Collaborate to Enhance Drug Development with AI

Incyte and Edison Scientific Collaborate to Enhance Drug Development with AI

Incyte and Edison Scientific Collaborate to Enhance Drug Development with AI
Trendline Trendline
Stilta Secures $10.5M Funding to Revolutionize Patent Discovery with AI

Stilta Secures $10.5M Funding to Revolutionize Patent Discovery with AI

Stilta Secures $10.5M Funding to Revolutionize Patent Discovery with AI
Trendline Trendline
OpenBind Launches AI Model to Revolutionize Drug Discovery with Large-Scale Data

OpenBind Launches AI Model to Revolutionize Drug Discovery with Large-Scale Data

OpenBind Launches AI Model to Revolutionize Drug Discovery with Large-Scale Data
Trendline Trendline
Akari Therapeutics Reports Increased Net Loss in Q1 2026

Akari Therapeutics Reports Increased Net Loss in Q1 2026

Akari Therapeutics Reports Increased Net Loss in Q1 2026
Trendline Trendline
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R Strategy

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R Strategy

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R Strategy
Trendline Trendline
OpenBind Introduces AI Model to Revolutionize Drug Discovery

OpenBind Introduces AI Model to Revolutionize Drug Discovery

OpenBind Introduces AI Model to Revolutionize Drug Discovery
Trendline Trendline
Parabilis Biotech Files for IPO to Fund Cancer Drug Trials

Parabilis Biotech Files for IPO to Fund Cancer Drug Trials

Parabilis Biotech Files for IPO to Fund Cancer Drug Trials
Trendline Trendline
FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements